Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela

Autores
Muñoz Calderon, Arturo Alejandro; Diaz Bello, Zoraida; Ramirez, José Luis; Noya, Oscar; Alarcón de Noya, Belkisyolé
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background & objectives: In Venezuela, Chagas disease (ChD) is considered a serious health problem, with about 6 million people at risk; and acute outbreaks due to oral transmission of Chagas Disease (OChD) are becoming increasingly important. In 2007 there was a major outbreak of OChD and although patients from this episode were treated with nifurtimox (Lampit®—Bayer), about 70% therapeutic failure was registered. These results led us to examine whether parasite’s drug susceptibility was related to this therapeutic failure. Methods: The Trypanosoma cruzi parasites were isolated by haemoculture of the peripheral blood drawn from the pre- and post-nifurtimox treated patients infected in the 2007 OChD outbreak at Caracas, Venezuela. The in vitro assays for drug testing were performed by the MTT methodology followed by calculation of inhibitory concentration-50 (IC50) values. Results: Parasite isolates obtained from the infected patients prior and after nifurtimox treatment when subjected to variable concentrations of the drug showed great heterogeneity in susceptibility with IC50 values ranging from 4.07 ± 1.82 to 94.92 ± 7.24 µM. Interpretation & conclusion: The high heterogeneity in nifurtimox IC50 values in the isolates and clones from the OChD patients, suggests that the therapeutic failure to nifurtimox could be due in part to a phenotypic variability that existed in the wild parasite population at the original source of contamination. Though, further pharmacological studies are needed to confirm the existence of natural nifurtimox resistance in the parasite.
Fil: Muñoz Calderon, Arturo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Central de Venezuela; Venezuela
Fil: Diaz Bello, Zoraida. Universidad Central de Venezuela; Venezuela
Fil: Ramirez, José Luis. Fundacion Instituto de Estudios Avanzados Idea; Venezuela
Fil: Noya, Oscar. Universidad Central de Venezuela; Venezuela. Ministerio del Poder Popular para la Salud; Venezuela
Fil: Alarcón de Noya, Belkisyolé. Universidad Central de Venezuela; Venezuela
Materia
CHAGAS DISEASE
ORAL TRANSMISSION
TRYPANOSOMA CRUZI
NIFURTIMOX
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/110255

id CONICETDig_82586250f0f0f62c6f67f1e9b5cf0fc4
oai_identifier_str oai:ri.conicet.gov.ar:11336/110255
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, VenezuelaMuñoz Calderon, Arturo AlejandroDiaz Bello, ZoraidaRamirez, José LuisNoya, OscarAlarcón de Noya, BelkisyoléCHAGAS DISEASEORAL TRANSMISSIONTRYPANOSOMA CRUZINIFURTIMOXhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Background & objectives: In Venezuela, Chagas disease (ChD) is considered a serious health problem, with about 6 million people at risk; and acute outbreaks due to oral transmission of Chagas Disease (OChD) are becoming increasingly important. In 2007 there was a major outbreak of OChD and although patients from this episode were treated with nifurtimox (Lampit®—Bayer), about 70% therapeutic failure was registered. These results led us to examine whether parasite’s drug susceptibility was related to this therapeutic failure. Methods: The Trypanosoma cruzi parasites were isolated by haemoculture of the peripheral blood drawn from the pre- and post-nifurtimox treated patients infected in the 2007 OChD outbreak at Caracas, Venezuela. The in vitro assays for drug testing were performed by the MTT methodology followed by calculation of inhibitory concentration-50 (IC50) values. Results: Parasite isolates obtained from the infected patients prior and after nifurtimox treatment when subjected to variable concentrations of the drug showed great heterogeneity in susceptibility with IC50 values ranging from 4.07 ± 1.82 to 94.92 ± 7.24 µM. Interpretation & conclusion: The high heterogeneity in nifurtimox IC50 values in the isolates and clones from the OChD patients, suggests that the therapeutic failure to nifurtimox could be due in part to a phenotypic variability that existed in the wild parasite population at the original source of contamination. Though, further pharmacological studies are needed to confirm the existence of natural nifurtimox resistance in the parasite.Fil: Muñoz Calderon, Arturo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Central de Venezuela; VenezuelaFil: Diaz Bello, Zoraida. Universidad Central de Venezuela; VenezuelaFil: Ramirez, José Luis. Fundacion Instituto de Estudios Avanzados Idea; VenezuelaFil: Noya, Oscar. Universidad Central de Venezuela; Venezuela. Ministerio del Poder Popular para la Salud; VenezuelaFil: Alarcón de Noya, Belkisyolé. Universidad Central de Venezuela; VenezuelaMalaria Research Centre2019-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/110255Muñoz Calderon, Arturo Alejandro; Diaz Bello, Zoraida; Ramirez, José Luis; Noya, Oscar; Alarcón de Noya, Belkisyolé; Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela; Malaria Research Centre; Journal Of Vector Borne Diseases; 56; 3; 9-2019; 237-2430972-9062CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4103/0972-9062.289397info:eu-repo/semantics/altIdentifier/url/http://www.jvbd.org/temp/JVectorBorneDis563237-9788681_024308.pdfinfo:eu-repo/semantics/altIdentifier/url/http://www.jvbd.org/downloadpdf.asp?issn=0972-9062;year=2019;volume=56;issue=3;spage=237;epage=243;aulast=Munoz-Calderon;type=2info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:24:08Zoai:ri.conicet.gov.ar:11336/110255instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:24:08.425CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela
title Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela
spellingShingle Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela
Muñoz Calderon, Arturo Alejandro
CHAGAS DISEASE
ORAL TRANSMISSION
TRYPANOSOMA CRUZI
NIFURTIMOX
title_short Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela
title_full Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela
title_fullStr Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela
title_full_unstemmed Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela
title_sort Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela
dc.creator.none.fl_str_mv Muñoz Calderon, Arturo Alejandro
Diaz Bello, Zoraida
Ramirez, José Luis
Noya, Oscar
Alarcón de Noya, Belkisyolé
author Muñoz Calderon, Arturo Alejandro
author_facet Muñoz Calderon, Arturo Alejandro
Diaz Bello, Zoraida
Ramirez, José Luis
Noya, Oscar
Alarcón de Noya, Belkisyolé
author_role author
author2 Diaz Bello, Zoraida
Ramirez, José Luis
Noya, Oscar
Alarcón de Noya, Belkisyolé
author2_role author
author
author
author
dc.subject.none.fl_str_mv CHAGAS DISEASE
ORAL TRANSMISSION
TRYPANOSOMA CRUZI
NIFURTIMOX
topic CHAGAS DISEASE
ORAL TRANSMISSION
TRYPANOSOMA CRUZI
NIFURTIMOX
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Background & objectives: In Venezuela, Chagas disease (ChD) is considered a serious health problem, with about 6 million people at risk; and acute outbreaks due to oral transmission of Chagas Disease (OChD) are becoming increasingly important. In 2007 there was a major outbreak of OChD and although patients from this episode were treated with nifurtimox (Lampit®—Bayer), about 70% therapeutic failure was registered. These results led us to examine whether parasite’s drug susceptibility was related to this therapeutic failure. Methods: The Trypanosoma cruzi parasites were isolated by haemoculture of the peripheral blood drawn from the pre- and post-nifurtimox treated patients infected in the 2007 OChD outbreak at Caracas, Venezuela. The in vitro assays for drug testing were performed by the MTT methodology followed by calculation of inhibitory concentration-50 (IC50) values. Results: Parasite isolates obtained from the infected patients prior and after nifurtimox treatment when subjected to variable concentrations of the drug showed great heterogeneity in susceptibility with IC50 values ranging from 4.07 ± 1.82 to 94.92 ± 7.24 µM. Interpretation & conclusion: The high heterogeneity in nifurtimox IC50 values in the isolates and clones from the OChD patients, suggests that the therapeutic failure to nifurtimox could be due in part to a phenotypic variability that existed in the wild parasite population at the original source of contamination. Though, further pharmacological studies are needed to confirm the existence of natural nifurtimox resistance in the parasite.
Fil: Muñoz Calderon, Arturo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Central de Venezuela; Venezuela
Fil: Diaz Bello, Zoraida. Universidad Central de Venezuela; Venezuela
Fil: Ramirez, José Luis. Fundacion Instituto de Estudios Avanzados Idea; Venezuela
Fil: Noya, Oscar. Universidad Central de Venezuela; Venezuela. Ministerio del Poder Popular para la Salud; Venezuela
Fil: Alarcón de Noya, Belkisyolé. Universidad Central de Venezuela; Venezuela
description Background & objectives: In Venezuela, Chagas disease (ChD) is considered a serious health problem, with about 6 million people at risk; and acute outbreaks due to oral transmission of Chagas Disease (OChD) are becoming increasingly important. In 2007 there was a major outbreak of OChD and although patients from this episode were treated with nifurtimox (Lampit®—Bayer), about 70% therapeutic failure was registered. These results led us to examine whether parasite’s drug susceptibility was related to this therapeutic failure. Methods: The Trypanosoma cruzi parasites were isolated by haemoculture of the peripheral blood drawn from the pre- and post-nifurtimox treated patients infected in the 2007 OChD outbreak at Caracas, Venezuela. The in vitro assays for drug testing were performed by the MTT methodology followed by calculation of inhibitory concentration-50 (IC50) values. Results: Parasite isolates obtained from the infected patients prior and after nifurtimox treatment when subjected to variable concentrations of the drug showed great heterogeneity in susceptibility with IC50 values ranging from 4.07 ± 1.82 to 94.92 ± 7.24 µM. Interpretation & conclusion: The high heterogeneity in nifurtimox IC50 values in the isolates and clones from the OChD patients, suggests that the therapeutic failure to nifurtimox could be due in part to a phenotypic variability that existed in the wild parasite population at the original source of contamination. Though, further pharmacological studies are needed to confirm the existence of natural nifurtimox resistance in the parasite.
publishDate 2019
dc.date.none.fl_str_mv 2019-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/110255
Muñoz Calderon, Arturo Alejandro; Diaz Bello, Zoraida; Ramirez, José Luis; Noya, Oscar; Alarcón de Noya, Belkisyolé; Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela; Malaria Research Centre; Journal Of Vector Borne Diseases; 56; 3; 9-2019; 237-243
0972-9062
CONICET Digital
CONICET
url http://hdl.handle.net/11336/110255
identifier_str_mv Muñoz Calderon, Arturo Alejandro; Diaz Bello, Zoraida; Ramirez, José Luis; Noya, Oscar; Alarcón de Noya, Belkisyolé; Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela; Malaria Research Centre; Journal Of Vector Borne Diseases; 56; 3; 9-2019; 237-243
0972-9062
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.4103/0972-9062.289397
info:eu-repo/semantics/altIdentifier/url/http://www.jvbd.org/temp/JVectorBorneDis563237-9788681_024308.pdf
info:eu-repo/semantics/altIdentifier/url/http://www.jvbd.org/downloadpdf.asp?issn=0972-9062;year=2019;volume=56;issue=3;spage=237;epage=243;aulast=Munoz-Calderon;type=2
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Malaria Research Centre
publisher.none.fl_str_mv Malaria Research Centre
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614237893165056
score 13.070432